NARCAN INJECTION

Toxicity, opioid (narcotic)- [Endotracheal] , intravenous (preferred in emergencies), intramuscular, or subcutaneous, 400 mcg (0.4 mg) to 2 mg as a single dose . The intravenous dose may be repeated at two- to three-minute intervals as needed . Note: If the patient is suspected of being physically dependent on an opioid medication and is not in immediate danger, the dose may be reduced to 100 to 200 mcg (0.1 to 0.2 mg). This dose may be repeated at two- to three-minute intervals as needed. Additional single doses of naloxone may be administered intravenously as needed. However, longer-lasting effects may be obtained if supplemental doses are administered via the intramuscular route. Also, initial treatment may be followed by continuous intravenous infusion of naloxone, with adjustment of the infusion rate according to the response of the patient. Respiratory depression, opioid (narcotic)-induced- Intravenous, 100 to 200 mcg (0.1 to 0.2 mg) every two to three minutes until adequate ventilation and alertness without significant pain are obtained . If necessary, the dose may be repeated at one- or two-hour intervals . Note: The dose should be titrated to avoid interference with control of postoperative pain; initial doses as low as 0.5 mcg (0.0005 mg) per kg of body weight have been recommended. Shock, septic - Intravenous, 30 mcg (0.03 mg) to 200 mcg (0.2 mg) per kg of body weight initially, followed by an intravenous infusion of 0.03 to 0.3 mg per kg of body weight per hour for one to twenty-four hours . Note: The optimal dose of naloxone in the treatment of hypotension due to septic shock has not been established . Some patients unresponsive to fluids and pressor agents experience an immediate, transient increase in blood pressure after receiving naloxone . The effectiveness of naloxone appears to be greater if it is administered early in the course of septic shock . The use of naloxone as an adjunctive treatment for hypotension in septic shock has not been shown to reduce mortality . [Opioid dependence diagnosis] - Intravenous, 200 mcg (0.2 mg) initially, followed by 600 mcg (0.6 mg) thirty seconds later if withdrawal symptoms are not apparent ; or Subcutaneous, 800 mcg (0.8 mg) . If necessary to confirm that the patient is not opioid-dependent, a rechallenge with 1.6 mg of naloxone administered intravenously may be performed.

MAXIMUM ADULT DOSE:

PEDIATRIC DOSE:

Toxicity, opioid (narcotic)- [Endotracheal] , intravenous (preferred in emergencies), intramuscular, or subcutaneous, 10 mcg (0.01 mg) per kg of body weight. If this dose does not result in improvement in the condition of the patient, an additional 100 mcg (0.1 mg) per kg of body weight may be given . Note: Doses higher than those listed above have been used to treat opioid toxicity . The American Academy of Pediatrics (AAP) recommends an initial dose of 0.1 mg per kg of body weight for infants and children up to 5 years of age and weighing less than twenty kg. For children 5 years of age and older or weighing more than twenty kg, an initial dose of 2 mg is recommended by AAP . Respiratory depression, opioid (narcotic)-induced- Intravenous, 5 to 10 mcg (0.005 to 0.01 mg) every two to three minutes until adequate ventilation and alertness without significant pain are obtained. If necessary, the dose may be repeated at one- or two-hour intervals . Respiratory depression, opioid (narcotic)-induced, neonatal- Intravenous via the umbilical vein (preferred), intramuscular, or subcutaneous, 10 mcg (0.01 mg) per kg of body weight. The intravenous dose may be repeated at two- to three-minute intervals until the desired response is obtained.

MAXIMUM PEDIATRIC DOSE:

ELDERLY DOSE:

PREVIOUS

NEXT